Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396862 · ClinicalTrials.gov registry record
Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 272
- Enrollment target
NCT02396862: Completed study, sponsored by Bayer.
NCT02396862 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 272 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02396862 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 272 participants
- Enrollment target
Study Summary
The purpose of the study is to improve the understanding of key patient reported outcomes such as quality of life as well as clinical outcomes in hemophilia A, in a global real world setting.
Interventions
- DRUG Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 272 participants |
| Start Date | 2015-12-09 |
| Est. Completion | 2018-03-26 |
What the finished NCT02396862 record still lists
NCT02396862 is an observational study that tracks outcomes without assigning an intervention. The registered 272 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222) is the first listed.
NCT02396862 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02396862 about?
NCT02396862 is a clinical study titled "Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment". The purpose of the study is to improve the understanding of key patient reported outcomes such as quality of life as well as clinical outcomes in hemophilia A, in a global real world setting.
What is the current status of trial NCT02396862?
This trial is currently completed. The enrollment target is 272 participants. The study started on 2015-12-09. Estimated completion is 2018-03-26.
What interventions are being tested in trial NCT02396862?
The interventions under investigation include: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222) (DRUG).
Who is sponsoring clinical trial NCT02396862?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02468024 · 272 participants · Phase 3
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
- NCT05519449 · 272 participants · Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- NCT06035939 · 272 participants · NA
SMYLS Multi-site Trial
- NCT06083051 · 272 participants · NA
Differences in Postoperative Symptoms With Four Ureteral Stents
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI